Alerts will be sent to your verified email
Verify EmailSUVEN
|
Suven Life Sciences
|
Cohance Lifesciences
|
Hikal
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
R&D as a % of Total Sales
|
2132.75 % | 4.19 % | 4.42 % |
|
Financials
|
|||
|
5 yr Average ROE
|
0.0 | 22.91 % | 9.85 % |
|
5yr average Equity Multiplier
|
1.55 | 1.35 | 2.2 |
|
5yr Average Asset Turnover Ratio
|
0.05 | 0.56 | 0.77 |
|
5yr Avg Net Profit Margin
|
-1150.51 % | 30.38 % | 5.73 % |
|
Price to Book
|
11.97 | 2.91 | 2.12 |
|
P/E
|
0.0 | 56.47 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
97.84 Days | 49.95 Days | 40.84 Days |
|
Inventory Days
|
10.88 Days | 74.21 Days | 60.35 Days |
|
Days Receivable
|
71.91 Days | 63.71 Days | 105.26 Days |
|
Days Payable
|
0.0 | 80.35 Days | 105.0 Days |
|
5yr Average Interest Coverage Ratio
|
-373.47 | 49.87 | 4.65 |
|
5yr Avg ROCE
|
-82.34 % | 27.5 % | 12.68 % |
|
5yr Avg Operating Profit Margin
|
-1227.3 % | 40.14 % | 16.33 % |
|
5 yr average Debt to Equity
|
0.0 | 0.06 | 0.65 |
|
5yr CAGR Net Profit
|
17.38 % | -5.86 % | -7.37 % |
|
5yr Average Return on Assets
|
-54.63 % | 17.54 % | 4.51 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
70.15 % | 57.49 % | 68.85 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.58 % | -2.51 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
1.78 % | 10.01 % | 4.13 % |
|
Suven Life Sciences
|
Cohance Lifesciences
|
Hikal
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
Asset Break-Up
|